NaviFUS

NaviFUS EBITDA per Share

The EBITDA per Share of NaviFUS (6872.TWO) as of Oct 15, 2026 is -2.26 TWD. In the previous year, EBITDA per Share was -1.78 TWD — a change of 26.96% (lower).

EBITDA per Share

-2.26TWD

YoY

26.96%

Last updated:

EBITDA per Share of NaviFUS is 2025 -2.26 TWD. EBITDA per Share of NaviFUS was 2024 -1.78 TWD. It decreases by 26.96% lower compared to the previous year.

The NaviFUS EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-1.06 TWD
Jan 1, 2020
-1.14 TWD
Jan 1, 2021
-1.45 TWD
Jan 1, 2022
-1.28 TWD
Jan 1, 2023
-1.34 TWD
Jan 1, 2024
-1.78 TWD
Jan 1, 2025
-2.26 TWD
The NaviFUS EBITDA per Share history
YEAREBITDA per ShareYoY
-2.26TWD+26.96%
-1.78TWD+32.57%
-1.34TWD+4.84%
-1.28TWD-11.72%
-1.45TWD+27.38%
-1.14TWD+7.77%
-1.06TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NaviFUS Stock analysis

What does NaviFUS do? NaviFUS Corp, listed on the Taiwan Stock Exchange under ticker 6872.TWO with ISIN TW0006872005, is a health care company headquartered in Taipei City, Taiwan. The company went public on June 22, 2022. NaviFUS Corp operates as a medical device company specializing in the development of two core technology platforms: focused ultrasound systems and therapeutic guidance tracking systems. The firm's focus includes the development of medical systems targeting recurrent brain tumors and Alzheimer's disease. The company's website is https://navifus.com/. NaviFUS Corp is engaged in the health care sector, specifically within the health care industry. The company's operations are centered on advancing medical technologies for neurological conditions, with an emphasis on non-invasive treatment approaches. While the company's specific products and market presence are not detailed in the provided information, its technological focus suggests a commitment to innovative solutions in neurology and neurosurgery. The firm's public listing in 2022 marks its transition into a publicly traded entity, reflecting its growth and development in the medical device sector. NaviFUS Corp's headquarters in Taipei City positions it within Taiwan's growing health care technology landscape, contributing to regional advancements in medical innovation. NaviFUS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NaviFUS stock

EBITDA per Share of NaviFUS is -2.26 TWD in 2025.

EBITDA per Share of NaviFUS changed from -1.78 TWD to -2.26 TWD, representing a 26.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share NaviFUS since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — NaviFUS

All Key Metrics — NaviFUS